COST-EFFECTIVENESS OF USING DAPAGLIFLOZIN IN THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION: A PHARMACOECONOMIC MODEL ANALYSIS

被引：0
|
作者：
Cavusoglu, Y. [1 ]
Demir, O. [2 ]
Dinc, M. [3 ]
Ozsoy, A. [3 ]
Erdogan, A. [3 ]
Ozer, S. [4 ]
机构：
[1] Eskisehir Osmangazi Univ, Fac Med, Istanbul 34, Turkey
[2] Ankara Univ, Fac Med, Ankara, Turkey
[3] AstraZeneca, Istanbul, Turkey
[4] Omega CRO, Ankara, Turkey
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSA166
引用
收藏
页码：S66 / S66
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
    Isaza, Nicolas
    Calvachi, Paola
    Raber, Inbar
    Liu, Chia-Liang
    Bellows, Brandon K.
    Hernandez, Inmaculada
    Shen, Changyu
    Gavin, Michael C.
    Garan, A. Reshad
    Kazi, Dhruv S.
    JAMA NETWORK OPEN, 2021, 4 (07) : E2114501
  • [2] Dapagliflozin for the treatment of heart failure with reduced ejection fraction in Brazil: a cost-effectiveness analysis
    Naves, Marcio Coutinho Xavier
    Amato, Angelica Amorim
    Zimmermann, Ivan Ricardo
    Peixoto, Henry Maia
    LANCET REGIONAL HEALTH-AMERICAS, 2025, 42
  • [3] Cost-effectiveness of Dapagliflozin in Heart Failure With Reduced Ejection Fraction
    Isaza, Nicolas
    Calvachi, Paola
    Raber, Inbar
    Shen, Changyu
    Gavin, Michael C.
    Garan, A. Reshad
    Bellows, Brandon K.
    Kazi, Dhruv S.
    CIRCULATION, 2020, 142
  • [4] Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction
    Parizo, Justin T.
    Goldhaber-Fiebert, Jeremy D.
    Salomon, Joshua A.
    Khush, Kiran K.
    Spertus, John A.
    Heidenreich, Paul A.
    Sandhu, Alexander T.
    JAMA CARDIOLOGY, 2021, 6 (08) : 926 - 935
  • [5] Cost-effectiveness of dapagliflozin and empagliflozin for treatment of heart failure with reduced ejection fraction
    Nguyen, Bao-Ngoc
    Mital, Shweta
    Bugden, Shawn
    V. Nguyen, Hai
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 376 : 83 - 89
  • [6] COST-EFFECTIVENESS OF DAPAGLIFLOZIN VERSUS SACUBITRIL/VALSARTAN FOR THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION
    McEwan, P.
    Darlington, O.
    Bergenheim, K.
    Qin, L.
    VALUE IN HEALTH, 2020, 23 : S494 - S494
  • [7] COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN THE TREATMENT OF CHRONIC SYMPTOMATIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN THE NETHERLANDS
    Kvamme, I
    de Graaf, G.
    Nekerman, S.
    Gijsbers, S.
    Wester, V
    Hoogendoorn, M.
    VALUE IN HEALTH, 2022, 25 (12) : S170 - S170
  • [8] Cost-effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China
    Yao, Younan
    Zhang, Rongcheng
    An, Tao
    Zhao, Xinke
    Zhang, Jian
    ESC HEART FAILURE, 2020, 7 (06): : 3582 - 3592
  • [9] Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review
    Ghader Mohammadnezhad
    Behniya Azadmehr
    Mehdi Mirheidari
    Nazila Yousefi
    Cost Effectiveness and Resource Allocation, 20
  • [10] Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review
    Mohammadnezhad, Ghader
    Azadmehr, Behniya
    Mirheidari, Mehdi
    Yousefi, Nazila
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2022, 20 (01)
12345